4D Molecular Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 147
- Market Cap
- $807M
- Introduction
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
4D-150 in Patients With Diabetic Macular Edema
- Conditions
- Diabetic RetinopathyDiabetic Macular Edema
- Interventions
- Biological: 4D-150 IVTBiological: Aflibercept IVT
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- 4D Molecular Therapeutics
- Target Recruit Count
- 72
- Registration Number
- NCT05930561
- Locations
- 🇺🇸
Retina Vitreous Associates of Florida, Saint Petersburg, Florida, United States
🇺🇸Retinal Research Institute LLC, Phoenix, Arizona, United States
🇺🇸Retina Consultants of Southern Colorado, Colorado Springs, Colorado, United States
4D-310 in Adults With Fabry Disease and Cardiac Involvement
- Conditions
- Fabry Disease
- Interventions
- Biological: 4D-310
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- 4D Molecular Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT05629559
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
🇦🇺Royal Perth Hospital, Perth, Australia
🇦🇺Royal Melbourne Hospital, Melbourne, Australia
4D-710 in Adult Patients with Cystic Fibrosis
- Conditions
- Cystic Fibrosis Lung
- Interventions
- Biological: 4D-710
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- 4D Molecular Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT05248230
- Locations
- 🇺🇸
University of Alabama Child Health Research Unit, Birmingham, Alabama, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸National Jewish Health, Denver, Colorado, United States
4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration
- Conditions
- Neovascular (Wet) Age-Related Macular Degeneration
- Interventions
- Biological: Aflibercept IVTBiological: 4D-150 IVT
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- 4D Molecular Therapeutics
- Target Recruit Count
- 215
- Registration Number
- NCT05197270
- Locations
- 🇺🇸
Barnet Delaney Perkins Eye Center, Phoenix, Arizona, United States
🇺🇸California Retina Consultants, Oxnard, California, United States
🇺🇸Retinal Consultants Medical Group, Sacramento, California, United States
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease
- Conditions
- Fabry Disease
- Interventions
- Biological: 4D-310
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- 4D Molecular Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT04519749
- Locations
- 🇺🇸
University of California at San Diego, La Jolla, California, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Lysosomal & Rare Disorders Research & Treatment Center, Inc, Fairfax, Virginia, United States
4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- Other: ObservationalBiological: 4D-125 IVT Injection
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- 4D Molecular Therapeutics
- Target Recruit Count
- 21
- Registration Number
- NCT04517149
- Locations
- 🇺🇸
Columbia University Medical Center/Edward Harkness Eye Institute, New York, New York, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸Vitreo Retinal Associates, Gainesville, Florida, United States
Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia
- Conditions
- Choroideremia
- Interventions
- Biological: 4D-110
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- 4D Molecular Therapeutics
- Target Recruit Count
- 13
- Registration Number
- NCT04483440
- Locations
- 🇺🇸
Moran Eye Center, University of Utah, Salt Lake City, Utah, United States
🇺🇸Retina Foundation of the Southwest, Dallas, Texas, United States
"Natural History" Study of Choroideremia
- Conditions
- Choroideremia
- Interventions
- Other: Observation
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- 4D Molecular Therapeutics
- Target Recruit Count
- 57
- Registration Number
- NCT02994368
- Locations
- 🇺🇸
Retina Foundation of the Southwest, Dallas, Texas, United States
🇺🇸Baylor College of Medicine, Ophthalmology-Cullen Eye Center, Houston, Texas, United States
🇨🇦University of Alberta, Edmonton, Alberta, Canada